TPST at a glance
The past year
Chart−95.7% $0.37, close Nov 13
- From the highest close
- −96.0%
- Vs the 200-day average
- −73.2%
Short interest
History241,168 shares
- Of shares outstanding
- 1.21%
- Since the last report
- −22.9%
- Days to cover
- 1.9 days
- Settled
- Oct 30, 2026
Insider buying, 7 days
FilingsNone filed this week
- Form 4s filed
- Nov 10 – Nov 16
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
TPST price history
Loading recent earnings…
Investment thesis
What must happen next
The portfolio only becomes a real economic asset if its cell therapy and small molecule candidates produce differentiated clinical evidence that a partner, regulator, or acquirer can underwrite.HoldingMateriality: High
The profile describes Tempest as a clinical-stage biotechnology company advancing a diversified portfolio of cell therapy and small molecule product candidates. If this holds, the company can move from cash-burning R&D option to partnerable drug-development platform; if it breaks, the equity is mainly a declining cash balance.
Watch: A trial readout shows insufficient efficacy, unacceptable safety, or no clinically meaningful differentiation versus the relevant standard of care.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
The profile describes Tempest as a clinical-stage biotechnology company advancing a diversified portfolio of cell therapy and small molecule product.
Open source ↗Financing capacity, not current demand, is the binding operating constraint because the company must fund clinical development before any commercial cash engine exists.WeakeningMateriality: High
Cash was $7.7 million at FY2025 year-end, down from $30.3 million at FY2024 year-end. If Tempest funds the next value-inflection point, common holders retain the clinical option; if it cannot, dilution, program delays, or restructuring dominate the outcome.
Watch: A strategic partnership or licensing deal provides meaningful upfront funding.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Cash was $7.7 million at FY2025 year-end, down from $30.3 million at FY2024 year-end.
Open source ↗Management must keep burn aligned with the most valuable clinical decisions, because unfocused trial spending would force financing before the portfolio has been de-risked.HoldingMateriality: Medium
FY2025 annual GAAP operating cash flow was negative $26.8 million, an improvement from negative $33.0 million in FY2024. Disciplined burn increases the chance that the next raise or partnership follows value creation rather than distress; undisciplined burn transfers value to new capital providers.
Watch: Trial expansions, manufacturing commitments, or CRO cost inflation materially increase required spending before a data event.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2025 annual GAAP operating cash flow was negative $26.8 million, an improvement from negative $33.0 million in FY2024.
Open source ↗The stock can work only if new capital is raised on terms that preserve existing shareholders' claim on the pipeline, rather than merely keeping the company alive.WeakeningMateriality: Medium
Stockholders' equity fell to $6.7 million at FY2025 year-end from $19.1 million at FY2024 year-end. Clinical success can still be a poor investment outcome if repeated distressed financings absorb most of the upside.
Watch: A non-dilutive partnership validates a program and funds development.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Stockholders' equity fell to $6.7 million at FY2025 year-end from $19.1 million at FY2024 year-end.
Open source ↗The stated diversified portfolio only protects investors if more than one program remains scientifically credible and fundable; otherwise Tempest becomes a single-asset binary bet.HoldingMateriality: Medium
The profile describes a diversified portfolio of cell therapy and small molecule product candidates. Real portfolio breadth gives management more paths to a partner or financing; hollow diversification leaves shareholders exposed to one clinical failure.
Watch: Management discontinues or indefinitely pauses most non-lead programs due to cash limits.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
The profile describes a diversified portfolio of cell therapy and small molecule product candidates.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
The portfolio only becomes a real economic asset if its cell therapy and small molecule candidates produce differentiated clinical evidence that a partner, regulator, or acquirer can underwrite. If this holds, the company can move from cash-burning R&D option to partnerable drug-development platform; if it breaks, the equity is mainly a declining cash balance.
Financing capacity, not current demand, is the binding operating constraint because the company must fund clinical development before any commercial cash engine exists. If Tempest funds the next value-inflection point, common holders retain the clinical option; if it cannot, dilution, program delays, or restructuring dominate the outcome.
Management must keep burn aligned with the most valuable clinical decisions, because unfocused trial spending would force financing before the portfolio has been de-risked. Disciplined burn increases the chance that the next raise or partnership follows value creation rather than distress; undisciplined burn transfers value to new capital providers.
The stock can work only if new capital is raised on terms that preserve existing shareholders' claim on the pipeline, rather than merely keeping the company alive. Clinical success can still be a poor investment outcome if repeated distressed financings absorb most of the upside.
The stated diversified portfolio only protects investors if more than one program remains scientifically credible and fundable; otherwise Tempest becomes a single-asset binary bet. Real portfolio breadth gives management more paths to a partner or financing; hollow diversification leaves shareholders exposed to one clinical failure.
All standing thesis claims
Original report summary
Tempest Therapeutics is not yet a commercial business; it is an R&D option whose value depends on converting a clinical-stage portfolio into compelling data and financing it without destroying per-share upside.
Bull case and bear case
Bull case and bear case for Tempest Therapeutics
Where the evidence on Tempest Therapeutics disagrees: Mixed on the latest evidence (Oct 15, 2026). Of its 5 thesis points, 3 holding and 2 weakening.
Bull case: what the evidence supports
The portfolio only becomes a real economic asset if its cell therapy and small molecule candidates produce differentiated clinical evidence that a partner, regulator, or acquirer can underwrite.
Management must keep burn aligned with the most valuable clinical decisions, because unfocused trial spending would force financing before the portfolio has been de-risked.
The stated diversified portfolio only protects investors if more than one program remains scientifically credible and fundable; otherwise Tempest becomes a single-asset binary bet.
Bear case: what the evidence questions
Financing capacity, not current demand, is the binding operating constraint because the company must fund clinical development before any commercial cash engine exists.
The stock can work only if new capital is raised on terms that preserve existing shareholders' claim on the pipeline, rather than merely keeping the company alive.
Thesis-Break Engine
What has broken in Tempest Therapeutics’s thesis
Each break OptimistFi flagged on Tempest Therapeutics, dated — with what has historically followed the same kind of break across the market, not a forecast for Tempest Therapeutics.
- CEO / officer changecondition set before this filing
Across all companies, this kind of break has happened 16,849 times before. Those stocks trailed comparable companies by a median of 2% over the next six months, and 38% of them trailed it by 10 points or more.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedEntered a material definitive agreement.
Tempest Therapeutics filed an SEC 8-K on 2026-09-28: Entered a material definitive agreement. It is a dated development that tests the current thesis.
- MixedEntered a material definitive agreement.
Tempest Therapeutics filed an SEC 8-K on 2026-09-17: Entered a material definitive agreement. It is a dated development that tests the current thesis.
- MixedOther material event.
Tempest Therapeutics filed an SEC 8-K on 2026-09-16: Other material event. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- A trial readout shows insufficient efficacy, unacceptable safety, or no clinically meaningful differentiation versus the relevant standard of care.
- A strategic partnership or licensing deal provides meaningful upfront funding.
- Trial expansions, manufacturing commitments, or CRO cost inflation materially increase required spending before a data event.
- A non-dilutive partnership validates a program and funds development.
- Management discontinues or indefinitely pauses most non-lead programs due to cash limits.
TPST news
Loading headlines…
Financial statements
TPST income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
TPST: quick answers
- When does Tempest Therapeutics (TPST) report earnings next?
- Tempest Therapeutics's next results are projected for February 12, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 13, 2026. Earnings calendar
- What is TPST's short interest?
- As of October 30, 2026, 241,168 TPST shares were sold short, 1.21% of its shares outstanding, down 22.9% from the count before. At the stock's average daily volume that is 1.9 days to cover. FINRA publishes the count twice a month. TPST short interest history

